Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
| NCT number | NCT02164513 |
| Other study ID # | 116855 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | |
| Last updated | |
| Start date | June 30, 2014 |
| Est. completion date | July 17, 2017 |
| Verified date | August 2018 |
| Source | GlaxoSmithKline |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the use of an 'open' triple therapy (use of Inhaled Corticosteroid [ICS]/ Long-acting Muscarinic Receptor Antagonists [LAMA])/ Long Acting Beta-Agonist [LABA] delivered via multiple inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile with dual or monotherapy doses for periods of up to one year. Given the clinical experience with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from their known pharmacology, the potential benefit of a new therapy option in patients with moderate to severe COPD supports the further development of the closed triple combination (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD
| Status | Completed |
| Enrollment | 10355 |
| Est. completion date | July 17, 2017 |
| Est. primary completion date | July 17, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 40 Years and older |
| Eligibility |
Inclusion Criteria: - Informed Consent: A signed and dated written informed consent prior to study participation - Type of subject: Outpatient - Age: Subjects 40 years of age or older at Visit 1 - Gender: Male or female subjects. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, > 45 years, in the absence of hormone replacement therapy OR Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to safety follow-up contact): Abstinence; Oral Contraceptive, either combined or progestogen alone; Injectable progestogen; Implants of levonorgestrel; Estrogenic vaginal ring; Percutaneous contraceptive patches; Intrauterine device (IUD) or intrauterine system (IUS); Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records. Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository) - COPD Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society - Smoking History: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at screening (visit 1) [number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or cigar use cannot be used to calculate pack-year history - Severity of COPD symptoms: A score of >=10 on the COPD Assessment Test (CAT) at screening - Severity of COPD Disease: A post-albuterol/salbutamol FEV1/ Forced Vital Capacity (FVC) ratio of <0.70 at Screening - Existing COPD maintenance treatment: Subject must be receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening. Note: Subjects receiving only Pro re nata (PRN) COPD medications are not eligible - History of Exacerbations: Subjects must demonstrate: a post-bronchodilator FEV1 <50% predicted normal and a documented history of >= 1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator 50% <=FEV1 < 80% predicted normal and a documented history of >= 2 moderate exacerbations or a documented history of >=1 severe COPD exacerbation (hospitalized) in the previous 12 months. Note: Percent predicted will be calculated using the European Respiratory Society Global Lung Function Initiative reference equations. Note: A documented history of a COPD exacerbation (e.g., medical record verification) is a medical record of worsening COPD symptoms that required systemic/oral corticosteroids and/or antibiotics (for a moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of antibiotics alone does not qualify as an exacerbation history unless the use was associated with treatment of worsening symptoms of COPD, such as increased dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable - Liver function tests: alanine aminotransferase (ALT) <2x upper limit of normal (ULN); alkaline phosphatase <=1.5xULN; bilirubin <=1.5xULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) - French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category Exclusion Criteria: - Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study - Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD) - Alpha1-antitrypsin deficiency: Subjects with Alpha1-antitrypsin deficiency as the underlying cause of COPD - Other respiratory disorders: Subjects with active tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases - Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening - Risk Factors for Pneumonia: immune suppression (e.g. human immunodeficiency virus [HIV], Lupus) or other risk factors for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's Disease, Myasthenia Gravis). Patients at potentially high risk (e.g. very low BMI, severely malnourished, or very low FEV1) will only be included at the discretion of the Investigator - Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable). In addition, any subject that experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in period will be excluded - Other Respiratory tract infections that have not resolved at least 7 days prior to screening - Abnormal Chest x-ray(CXR): Chest x-ray (posteroanterior and lateral) reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on CXR (e.g. significant cardiomegaly, pleural effusion or scarring). All subjects will have a chest x-ray at Screening Visit 1 (or historical radiograph or computerised tomography (CT) scan obtained within 3 months prior to screening) that will be over-read by a central vendor. Note: Subjects who have experienced pneumonia and/or moderate or severe COPD exacerbation within 3 months of screening must provide a post pneumonia/exacerbation chest x-ray to be over-read by the central vendor or have a chest x-ray conducted at screening. For sites in Germany: If a chest x-ray (or CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for Radiation Protection (Bundesamt für Strahlenschutz [BfS]) - Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study - Unstable liver disease as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). - Note: Chronic stable hepatitis B and C are acceptable if the subject otherwise meets entry criteria - Unstable or life threatening cardiac disease: subjects with any of the following at Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure - Abnormal and clinically significant 12-Lead Electrocardiogram (ECG) finding: Investigators will be provided with ECG reviews conducted by a centralized independent cardiologist to assist in evaluation of subject eligibility. The Principal Investigator will determine the clinical significance of each abnormal ECG finding in relation to the subject's medical history and exclude subjects who would be at undue risk by participating in the trial. An abnormal and clinically significant finding that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following: atrial fibrillation (AF) with rapid ventricular rate >120 beats per minute); sustained or nonsustained ventricular tachycardia (VT); Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted); QT interval corrected for heart rate (QTcF) >=500 milliseconds (msec) in patients with QRS <120 msec and QTcF >=530 msec in patients with QRS >=120 msec - Contraindications: A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the Investigator contraindicates study participation - Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting period if the subject has been considered cured by treatment - Oxygen therapy: Use of long-term oxygen therapy (LTOT) described as resting oxygen therapy >3 Liter/minute (L/min) (Oxygen use =<3L/min flow is not exclusionary) - Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol/salbutamol for the 4-hour period required prior to spirometry testing at each study visit - Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded - Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years - Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits - Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study - Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or study site, or immediate family members of the aforementioned that is involved with this study - Inability to read: In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete study related materials - Medication prior to screening: Use of the following medications within the following time intervals prior to Screening (Visit 1) or during the study: Long term antibiotic therapy Subjects receiving antibiotics for long term therapy are not eligible for the study (Antibiotics are allowed for the short term treatment of an exacerbation or for short term treatment of other acute infections during the study); Systemic, Oral, parenteral corticosteroids 30 days (Except during the study oral/systemic corticosteroids may be used to treat COPD exacerbations/pneumonia) Intra-articular injections are allowed; Any other investigational drug (30 days or 5 half lives whichever is longer) |
| Country | Name | City | State |
|---|---|---|---|
| Argentina | GSK Investigational Site | Bahía Blanca | Buenos Aires |
| Argentina | GSK Investigational Site | Berazategui | |
| Argentina | GSK Investigational Site | Berazategui, Buenos Aires | |
| Argentina | GSK Investigational Site | Buenos Aires | |
| Argentina | GSK Investigational Site | Buenos Aires | |
| Argentina | GSK Investigational Site | Buenos Aires | |
| Argentina | GSK Investigational Site | Caba | Buenos Aires |
| Argentina | GSK Investigational Site | Capital Federal | |
| Argentina | GSK Investigational Site | Ciudad Autonoma de Buenis Aires | |
| Argentina | GSK Investigational Site | Ciudad Autonoma de Buenos Aires | Buenos Aires |
| Argentina | GSK Investigational Site | Ciudad Autonoma de Buenos Aires | Buenos Aires |
| Argentina | GSK Investigational Site | Ciudad Autonoma de Buenos Aires | Buenos Aires |
| Argentina | GSK Investigational Site | Ciudad Autónoma de Buenos Aires | |
| Argentina | GSK Investigational Site | Ciudad Autónoma de Buenos Aires | |
| Argentina | GSK Investigational Site | Ciudad Autónoma de Buenos Aires | |
| Argentina | GSK Investigational Site | Concepcion del Uruguay | Entre Ríos |
| Argentina | GSK Investigational Site | Cordoba | |
| Argentina | GSK Investigational Site | Cordoba | Córdova |
| Argentina | GSK Investigational Site | Coronel Suarez | |
| Argentina | GSK Investigational Site | Florida | Buenos Aires |
| Argentina | GSK Investigational Site | La Plata | Buenos Aires |
| Argentina | GSK Investigational Site | Mar del Plata | Buenos Aires |
| Argentina | GSK Investigational Site | Mar del Plata | Buenos Aires |
| Argentina | GSK Investigational Site | Mendoza | |
| Argentina | GSK Investigational Site | Mendoza | |
| Argentina | GSK Investigational Site | Monte Grande | |
| Argentina | GSK Investigational Site | Nueve de Julio | Buenos Aires |
| Argentina | GSK Investigational Site | Paraná | Buenos Aires |
| Argentina | GSK Investigational Site | Rosario | Santa Fe |
| Argentina | GSK Investigational Site | Rosario | Santa Fe |
| Argentina | GSK Investigational Site | Salta | |
| Argentina | GSK Investigational Site | San Miguel de Tucuman | Tucumán |
| Argentina | GSK Investigational Site | San Miguel de Tucumán | |
| Argentina | GSK Investigational Site | San Rafael | Mendoza |
| Argentina | GSK Investigational Site | Santa Fe | |
| Argentina | GSK Investigational Site | Santa Rosa | |
| Argentina | GSK Investigational Site | Vicente Lopez | Buenos Aires |
| Australia | GSK Investigational Site | Adelaide | South Australia |
| Australia | GSK Investigational Site | Cairns | Queensland |
| Australia | GSK Investigational Site | Carina Heights | Queensland |
| Australia | GSK Investigational Site | Clayton | Victoria |
| Australia | GSK Investigational Site | Concord | New South Wales |
| Australia | GSK Investigational Site | Daw Park | South Australia |
| Australia | GSK Investigational Site | Footscray | Victoria |
| Australia | GSK Investigational Site | Frankston | Victoria |
| Australia | GSK Investigational Site | Geelong | Victoria |
| Australia | GSK Investigational Site | Gosford | New South Wales |
| Australia | GSK Investigational Site | Hamilton | Victoria |
| Australia | GSK Investigational Site | Liverpool | |
| Australia | GSK Investigational Site | Maroubra | New South Wales |
| Australia | GSK Investigational Site | Murdoch | Western Australia |
| Australia | GSK Investigational Site | Nedlands | Western Australia |
| Australia | GSK Investigational Site | Westmead | New South Wales |
| Austria | GSK Investigational Site | Feldbach | |
| Austria | GSK Investigational Site | Feldkirch | |
| Austria | GSK Investigational Site | Grieskirchen | |
| Austria | GSK Investigational Site | Thalheim bei Wels | |
| Austria | GSK Investigational Site | Vienna | |
| Belgium | GSK Investigational Site | Antwerpen | |
| Belgium | GSK Investigational Site | Brugge | |
| Belgium | GSK Investigational Site | Brussels | |
| Belgium | GSK Investigational Site | Erpent | |
| Belgium | GSK Investigational Site | Genk | |
| Belgium | GSK Investigational Site | Gent | |
| Belgium | GSK Investigational Site | Gilly | |
| Belgium | GSK Investigational Site | Hasselt | |
| Belgium | GSK Investigational Site | Liège | |
| Belgium | GSK Investigational Site | Malmedy | |
| Belgium | GSK Investigational Site | Mechelen | |
| Belgium | GSK Investigational Site | Montigny-Le-Tilleul | |
| Belgium | GSK Investigational Site | Oostende | |
| Belgium | GSK Investigational Site | Roeselaere | |
| Belgium | GSK Investigational Site | Turnhout | |
| Brazil | GSK Investigational Site | Blumenau | Santa Catarina |
| Brazil | GSK Investigational Site | Florianopolis | Santa Catarina |
| Brazil | GSK Investigational Site | Porto Alegre | Rio Grande Do Sul |
| Brazil | GSK Investigational Site | Porto Alegre | Rio Grande Do Sul |
| Brazil | GSK Investigational Site | Porto Alegre | Rio Grande Do Sul |
| Brazil | GSK Investigational Site | Recife | Pernambuco |
| Brazil | GSK Investigational Site | Rio de Janeiro | |
| Brazil | GSK Investigational Site | São Paulo | |
| Brazil | GSK Investigational Site | São Paulo | |
| Brazil | GSK Investigational Site | São Paulo | |
| Brazil | GSK Investigational Site | São Paulo | |
| Canada | GSK Investigational Site | Burlington | Ontario |
| Canada | GSK Investigational Site | Cornwall | Ontario |
| Canada | GSK Investigational Site | Edmonton | Alberta |
| Canada | GSK Investigational Site | Gatineau | Quebec |
| Canada | GSK Investigational Site | Hamilton | Ontario |
| Canada | GSK Investigational Site | Hamilton | Ontario |
| Canada | GSK Investigational Site | Mirabel | Quebec |
| Canada | GSK Investigational Site | Moncton | New Brunswick |
| Canada | GSK Investigational Site | Montréal | Quebec |
| Canada | GSK Investigational Site | Quebec | |
| Canada | GSK Investigational Site | Quebec | |
| Canada | GSK Investigational Site | Sarnia | Ontario |
| Canada | GSK Investigational Site | Sherwood Park | Alberta |
| Canada | GSK Investigational Site | St-Charles-Borromée | Quebec |
| Canada | GSK Investigational Site | Sudbury | Ontario |
| Canada | GSK Investigational Site | Sudbury | Ontario |
| Canada | GSK Investigational Site | Toronto | Ontario |
| Canada | GSK Investigational Site | Toronto | Ontario |
| Canada | GSK Investigational Site | Toronto | Ontario |
| Canada | GSK Investigational Site | Toronto | Ontario |
| Canada | GSK Investigational Site | Toronto | Ontario |
| Canada | GSK Investigational Site | Trois Rivieres | Quebec |
| Canada | GSK Investigational Site | Truro | Nova Scotia |
| Canada | GSK Investigational Site | Windsor | Ontario |
| Canada | GSK Investigational Site | Winnipeg | Manitoba |
| Canada | GSK Investigational Site | Winnipeg | Manitoba |
| Chile | GSK Investigational Site | Concepción | Región Del Biobio |
| Chile | GSK Investigational Site | Curicó | Región Del Maule |
| Chile | GSK Investigational Site | Puente Alto - Santiago | Región Metro De Santiago |
| Chile | GSK Investigational Site | Santiago | Región Metro De Santiago |
| Chile | GSK Investigational Site | Santiago | Región Metro De Santiago |
| Chile | GSK Investigational Site | Santiago | Región Metro De Santiago |
| Chile | GSK Investigational Site | Santiago | Región Metro De Santiago |
| Chile | GSK Investigational Site | Santiago | Región Metro De Santiago |
| Chile | GSK Investigational Site | Santiago | Región Metro De Santiago |
| Chile | GSK Investigational Site | Santiago | |
| Chile | GSK Investigational Site | Santiago | |
| Chile | GSK Investigational Site | Talca | Región Del Maule |
| Chile | GSK Investigational Site | Talcahuano | |
| Chile | GSK Investigational Site | Valparaiso | Valparaíso |
| Chile | GSK Investigational Site | Viña del Mar | Valparaíso |
| Chile | GSK Investigational Site | Viña del Mar | |
| China | GSK Investigational Site | Beijing | |
| China | GSK Investigational Site | Beijing | |
| China | GSK Investigational Site | Beijing | |
| China | GSK Investigational Site | Beijing | |
| China | GSK Investigational Site | Beijing | |
| China | GSK Investigational Site | Changchun | Jilin |
| China | GSK Investigational Site | Changsha | |
| China | GSK Investigational Site | Chengdu | Sichuan |
| China | GSK Investigational Site | Chongqing | |
| China | GSK Investigational Site | Chongqing | |
| China | GSK Investigational Site | Chongqing | |
| China | GSK Investigational Site | Fuzhou | |
| China | GSK Investigational Site | Guangzhou | |
| China | GSK Investigational Site | Guangzhou | Guangdong |
| China | GSK Investigational Site | Guangzhou | Guangdong |
| China | GSK Investigational Site | Guangzhou | Guangdong |
| China | GSK Investigational Site | Guangzhou | Guangdong |
| China | GSK Investigational Site | Guangzhou | Guangdong |
| China | GSK Investigational Site | Haikou | Hainan |
| China | GSK Investigational Site | Hangzhou | Zhejiang |
| China | GSK Investigational Site | Jinan | Shandong |
| China | GSK Investigational Site | Jinan | Shandong |
| China | GSK Investigational Site | Nanchang | Jiangxi |
| China | GSK Investigational Site | Nanchang | |
| China | GSK Investigational Site | Nanjing | Jiangsu |
| China | GSK Investigational Site | Nanjing | Jiangsu |
| China | GSK Investigational Site | Nanjing | Jiangsu |
| China | GSK Investigational Site | Nanning | Guangxi |
| China | GSK Investigational Site | Qingdao | Shandong |
| China | GSK Investigational Site | Shanghai | |
| China | GSK Investigational Site | Shanghai | |
| China | GSK Investigational Site | Shenyang | Liaoning |
| China | GSK Investigational Site | Shenyang | Liaoning |
| China | GSK Investigational Site | Shijiazhuang | Hebei |
| China | GSK Investigational Site | Taiyuan | Shanxi |
| China | GSK Investigational Site | Tianjin | |
| China | GSK Investigational Site | Wuxi | |
| China | GSK Investigational Site | Xian | Shanxi |
| China | GSK Investigational Site | Yinchuan | Ningxia |
| China | GSK Investigational Site | Zhanjiang | Guangdong |
| Colombia | GSK Investigational Site | Barranquilla | |
| Colombia | GSK Investigational Site | Bogota | |
| Colombia | GSK Investigational Site | Bogotá | |
| Colombia | GSK Investigational Site | Bogotá | |
| Colombia | GSK Investigational Site | Medellin | |
| Czechia | GSK Investigational Site | Benesov | |
| Czechia | GSK Investigational Site | Brandys nad Labem | |
| Czechia | GSK Investigational Site | Cvikov | |
| Czechia | GSK Investigational Site | Holesov | |
| Czechia | GSK Investigational Site | Hradec Kralove | |
| Czechia | GSK Investigational Site | Jaromer | |
| Czechia | GSK Investigational Site | Olomouc | |
| Czechia | GSK Investigational Site | Olomouc | |
| Czechia | GSK Investigational Site | Ostrava - Poruba | |
| Czechia | GSK Investigational Site | Plzen | |
| Czechia | GSK Investigational Site | Praha 5 | |
| Czechia | GSK Investigational Site | Praha 8 | |
| Czechia | GSK Investigational Site | Tabor | |
| Czechia | GSK Investigational Site | Teplice | |
| Czechia | GSK Investigational Site | Trebic | |
| Denmark | GSK Investigational Site | Aalborg | |
| Denmark | GSK Investigational Site | Aarhus C | |
| Denmark | GSK Investigational Site | Hellerup | |
| Denmark | GSK Investigational Site | Hvidovre | |
| Denmark | GSK Investigational Site | Kolding | |
| Denmark | GSK Investigational Site | Odense C | |
| Denmark | GSK Investigational Site | Roskilde | |
| Denmark | GSK Investigational Site | Sønderborg | |
| Finland | GSK Investigational Site | Espoo | |
| Finland | GSK Investigational Site | Helsinki | |
| Finland | GSK Investigational Site | Jyvaskyla | |
| Finland | GSK Investigational Site | Lohja | |
| Finland | GSK Investigational Site | Tampere | |
| Finland | GSK Investigational Site | Turku | |
| Finland | GSK Investigational Site | Turku | |
| France | GSK Investigational Site | Bayonne cedex | |
| France | GSK Investigational Site | Brest Cedex | |
| France | GSK Investigational Site | Briis-sous-Forge | |
| France | GSK Investigational Site | Grenoble cedex 9 | |
| France | GSK Investigational Site | Le Mans | |
| France | GSK Investigational Site | Lyon cedex 04 | |
| France | GSK Investigational Site | Marseille cedex 03 | |
| France | GSK Investigational Site | Montauban cedex | |
| France | GSK Investigational Site | Montpellier cedex 5 | |
| France | GSK Investigational Site | Nimes | |
| France | GSK Investigational Site | Orléans cedex 2 | |
| France | GSK Investigational Site | Paris | |
| France | GSK Investigational Site | Perpignan | |
| France | GSK Investigational Site | Pessac cedex | |
| France | GSK Investigational Site | Pringy cedex | |
| France | GSK Investigational Site | Rennes Cedex 9 | |
| France | GSK Investigational Site | Strasbourg cedex | |
| France | GSK Investigational Site | Toulon | |
| France | GSK Investigational Site | Vandoeuvre-les-Nancy | |
| Germany | GSK Investigational Site | Aschaffenburg | Bayern |
| Germany | GSK Investigational Site | Auerbach | Sachsen |
| Germany | GSK Investigational Site | Augsburg | Bayern |
| Germany | GSK Investigational Site | Bad Lippspringe | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Bad Woerrishofen | Bayern |
| Germany | GSK Investigational Site | Bamberg | Bayern |
| Germany | GSK Investigational Site | Bensheim | Hessen |
| Germany | GSK Investigational Site | Bergisch Gladbach | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Berlin | |
| Germany | GSK Investigational Site | Bernkastel-Kues | Rheinland-Pfalz |
| Germany | GSK Investigational Site | Bonn | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Bonn | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Cottbus | Brandenburg |
| Germany | GSK Investigational Site | Dachau | Bayern |
| Germany | GSK Investigational Site | Deggendorf | |
| Germany | GSK Investigational Site | Deggingen | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Delitzsch | Sachsen |
| Germany | GSK Investigational Site | Dillingen | Bayern |
| Germany | GSK Investigational Site | Donaustauf | Bayern |
| Germany | GSK Investigational Site | Dortmund | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Dueren | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Duisburg | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Essen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Essen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Frankenberg | Hessen |
| Germany | GSK Investigational Site | Frankfurt | Hessen |
| Germany | GSK Investigational Site | Frankfurt | Hessen |
| Germany | GSK Investigational Site | Freudenberg | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Fulda | Hessen |
| Germany | GSK Investigational Site | Fuldatal | Hessen |
| Germany | GSK Investigational Site | Garmisch-Partenirchen | Bayern |
| Germany | GSK Investigational Site | Gauting | Bayern |
| Germany | GSK Investigational Site | Geesthacht | Schleswig-Holstein |
| Germany | GSK Investigational Site | Gelsenkirchen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Gera | Thueringen |
| Germany | GSK Investigational Site | Gummersbach | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Hagen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Halberstadt | Sachsen-Anhalt |
| Germany | GSK Investigational Site | Halle | Sachsen-Anhalt |
| Germany | GSK Investigational Site | Hamburg | |
| Germany | GSK Investigational Site | Hamburg | |
| Germany | GSK Investigational Site | Hamburg | |
| Germany | GSK Investigational Site | Hannover | Niedersachsen |
| Germany | GSK Investigational Site | Hannover | Niedersachsen |
| Germany | GSK Investigational Site | Hettstedt | Sachsen-Anhalt |
| Germany | GSK Investigational Site | Kassel | Hessen |
| Germany | GSK Investigational Site | Kleve | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Koblenz | Rheinland-Pfalz |
| Germany | GSK Investigational Site | Koeln | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Landsberg | Bayern |
| Germany | GSK Investigational Site | Leipzg | Sachsen |
| Germany | GSK Investigational Site | Leipzig | Sachsen |
| Germany | GSK Investigational Site | Leipzig | Sachsen |
| Germany | GSK Investigational Site | Leipzig | Sachsen |
| Germany | GSK Investigational Site | Leipzig | Sachsen |
| Germany | GSK Investigational Site | Leonberg | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Luebeck | Schleswig-Holstein |
| Germany | GSK Investigational Site | Mainz | Rheinland-Pfalz |
| Germany | GSK Investigational Site | Mannheim | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Mannheim | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Marburg | Hessen |
| Germany | GSK Investigational Site | Muenchen | Bayern |
| Germany | GSK Investigational Site | Muenchen | Bayern |
| Germany | GSK Investigational Site | Neu isenburg | Hessen |
| Germany | GSK Investigational Site | Neu-Ulm | Bayern |
| Germany | GSK Investigational Site | Neuss | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Neuwied | Rheinland-Pfalz |
| Germany | GSK Investigational Site | Nuernberg | Bayern |
| Germany | GSK Investigational Site | Offenbach | Hessen |
| Germany | GSK Investigational Site | Peine | Niedersachsen |
| Germany | GSK Investigational Site | Potsdam | Brandenburg |
| Germany | GSK Investigational Site | Potsdam | Brandenburg |
| Germany | GSK Investigational Site | Rathenow | Brandenburg |
| Germany | GSK Investigational Site | Ratingen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Reinfeld | Schleswig-Holstein |
| Germany | GSK Investigational Site | Rheine | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Rodgau | Hessen |
| Germany | GSK Investigational Site | Rosenheim | Bayern |
| Germany | GSK Investigational Site | Ruedersdorf | Brandenburg |
| Germany | GSK Investigational Site | Ruesselsheim | Hessen |
| Germany | GSK Investigational Site | Saalfeld | Thueringen |
| Germany | GSK Investigational Site | Saarbruecken | Saarland |
| Germany | GSK Investigational Site | Schleswig | Schleswig-Holstein |
| Germany | GSK Investigational Site | Schmoelln | Thueringen |
| Germany | GSK Investigational Site | Solingen | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Stuttgart | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Stuttgart | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Teuchern | Sachsen-Anhalt |
| Germany | GSK Investigational Site | Wallerfing | Bayern |
| Germany | GSK Investigational Site | Wardenburg | Niedersachsen |
| Germany | GSK Investigational Site | Warendorf | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Wiesloch | Baden-Wuerttemberg |
| Germany | GSK Investigational Site | Wissen | Rheinland-Pfalz |
| Germany | GSK Investigational Site | Witten | Nordrhein-Westfalen |
| Germany | GSK Investigational Site | Witten | |
| Germany | GSK Investigational Site | Zerbst | Sachsen-Anhalt |
| Hong Kong | GSK Investigational Site | Kwun Tong | |
| Hong Kong | GSK Investigational Site | Lai Chi Kok | |
| Hong Kong | GSK Investigational Site | Pokfulam | |
| Hong Kong | GSK Investigational Site | Shatin | |
| Hong Kong | GSK Investigational Site | Tuen Mun | |
| Israel | GSK Investigational Site | Afula | |
| Israel | GSK Investigational Site | Ashkelon | |
| Israel | GSK Investigational Site | Haifa | |
| Israel | GSK Investigational Site | Holon | |
| Israel | GSK Investigational Site | Jerusalem | |
| Israel | GSK Investigational Site | Jerusalem | |
| Israel | GSK Investigational Site | Kfar-Saba | |
| Israel | GSK Investigational Site | Petah Tikva | |
| Israel | GSK Investigational Site | Ramat Gan | |
| Israel | GSK Investigational Site | Rehovot | |
| Israel | GSK Investigational Site | Tel Aviv | |
| Israel | GSK Investigational Site | Tel-Aviv | |
| Israel | GSK Investigational Site | Zrifin | |
| Japan | GSK Investigational Site | Aichi | |
| Japan | GSK Investigational Site | Aichi | |
| Japan | GSK Investigational Site | Aichi | |
| Japan | GSK Investigational Site | Aichi | |
| Japan | GSK Investigational Site | Aichi | |
| Japan | GSK Investigational Site | Aichi | |
| Japan | GSK Investigational Site | Aichi | |
| Japan | GSK Investigational Site | Chiba | |
| Japan | GSK Investigational Site | Chiba | |
| Japan | GSK Investigational Site | Ehime | |
| Japan | GSK Investigational Site | Fukuoka | |
| Japan | GSK Investigational Site | Fukuoka | |
| Japan | GSK Investigational Site | Fukuoka | |
| Japan | GSK Investigational Site | Fukuoka | |
| Japan | GSK Investigational Site | Fukuoka | |
| Japan | GSK Investigational Site | Fukuoka | |
| Japan | GSK Investigational Site | Gifu | |
| Japan | GSK Investigational Site | Gifu | |
| Japan | GSK Investigational Site | Gifu | |
| Japan | GSK Investigational Site | Gunma | |
| Japan | GSK Investigational Site | Gunma | |
| Japan | GSK Investigational Site | Hiroshima | |
| Japan | GSK Investigational Site | Hiroshima | |
| Japan | GSK Investigational Site | Hiroshima | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hokkaido | |
| Japan | GSK Investigational Site | Hyogo | |
| Japan | GSK Investigational Site | Hyogo | |
| Japan | GSK Investigational Site | Hyogo | |
| Japan | GSK Investigational Site | Hyogo | |
| Japan | GSK Investigational Site | Hyogo | |
| Japan | GSK Investigational Site | Hyogo | |
| Japan | GSK Investigational Site | Hyogo | |
| Japan | GSK Investigational Site | Hyogo | |
| Japan | GSK Investigational Site | Ibaraki | |
| Japan | GSK Investigational Site | Ibaraki | |
| Japan | GSK Investigational Site | Ibaraki | |
| Japan | GSK Investigational Site | Ibaraki | |
| Japan | GSK Investigational Site | Ibaraki | |
| Japan | GSK Investigational Site | Ishikawa | |
| Japan | GSK Investigational Site | Ishikawa | |
| Japan | GSK Investigational Site | Ishikawa | |
| Japan | GSK Investigational Site | Ishikawa | |
| Japan | GSK Investigational Site | Iwate | |
| Japan | GSK Investigational Site | Kagawa | |
| Japan | GSK Investigational Site | Kagawa | |
| Japan | GSK Investigational Site | Kagawa | |
| Japan | GSK Investigational Site | Kagawa | |
| Japan | GSK Investigational Site | Kanagawa | |
| Japan | GSK Investigational Site | Kanagawa | |
| Japan | GSK Investigational Site | Kanagawa | |
| Japan | GSK Investigational Site | Kanagawa | |
| Japan | GSK Investigational Site | Kanagawa | |
| Japan | GSK Investigational Site | Kanagawa | |
| Japan | GSK Investigational Site | Kochi | |
| Japan | GSK Investigational Site | Kumamoto | |
| Japan | GSK Investigational Site | Kyoto | |
| Japan | GSK Investigational Site | Kyoto | |
| Japan | GSK Investigational Site | Kyoto | |
| Japan | GSK Investigational Site | Mie | |
| Japan | GSK Investigational Site | Mie | |
| Japan | GSK Investigational Site | Miyagi | |
| Japan | GSK Investigational Site | Miyagi | |
| Japan | GSK Investigational Site | Miyagi | |
| Japan | GSK Investigational Site | Miyagi | |
| Japan | GSK Investigational Site | Nagano | |
| Japan | GSK Investigational Site | Niigata | |
| Japan | GSK Investigational Site | Oita | |
| Japan | GSK Investigational Site | Okayama | |
| Japan | GSK Investigational Site | Okayama | |
| Japan | GSK Investigational Site | Okayama | |
| Japan | GSK Investigational Site | Okinawa | |
| Japan | GSK Investigational Site | Okinawa | |
| Japan | GSK Investigational Site | Okinawa | |
| Japan | GSK Investigational Site | Okinawa | |
| Japan | GSK Investigational Site | Okinawa | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Osaka | |
| Japan | GSK Investigational Site | Saitama | |
| Japan | GSK Investigational Site | Shizuoka | |
| Japan | GSK Investigational Site | Shizuoka | |
| Japan | GSK Investigational Site | Tochigi | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Tokyo | |
| Japan | GSK Investigational Site | Toyama | |
| Japan | GSK Investigational Site | Toyama | |
| Japan | GSK Investigational Site | Wakayama | |
| Japan | GSK Investigational Site | Yamagata | |
| Japan | GSK Investigational Site | Yamanashi | |
| Japan | GSK Investigational Site | Yamanashi | |
| Korea, Republic of | GSK Investigational Site | Bucheon city, Gyenggi-do | |
| Korea, Republic of | GSK Investigational Site | Cheongju-si, Chungcheongbuk-do | |
| Korea, Republic of | GSK Investigational Site | Gyeonggi-do | |
| Korea, Republic of | GSK Investigational Site | Gyeonggi-do | |
| Korea, Republic of | GSK Investigational Site | Gyeonggi-do | |
| Korea, Republic of | GSK Investigational Site | Incheon | |
| Korea, Republic of | GSK Investigational Site | Incheon | |
| Korea, Republic of | GSK Investigational Site | Jeonju-si | |
| Korea, Republic of | GSK Investigational Site | Kangwon-do | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Seoul | |
| Korea, Republic of | GSK Investigational Site | Suwon | |
| Netherlands | GSK Investigational Site | Alkmaar | |
| Netherlands | GSK Investigational Site | Almelo | |
| Netherlands | GSK Investigational Site | Almelo | |
| Netherlands | GSK Investigational Site | Assen | |
| Netherlands | GSK Investigational Site | Beek | |
| Netherlands | GSK Investigational Site | Breda | |
| Netherlands | GSK Investigational Site | Den Bosch | |
| Netherlands | GSK Investigational Site | Dordrecht | |
| Netherlands | GSK Investigational Site | Eindhoven | |
| Netherlands | GSK Investigational Site | Enschede | |
| Netherlands | GSK Investigational Site | Groningen | |
| Netherlands | GSK Investigational Site | Harderwijk | |
| Netherlands | GSK Investigational Site | Helmond | |
| Netherlands | GSK Investigational Site | Hoofddorp | |
| Netherlands | GSK Investigational Site | Hoorn | |
| Netherlands | GSK Investigational Site | Kloosterhaar | |
| Netherlands | GSK Investigational Site | Leeuwarden | |
| Netherlands | GSK Investigational Site | Nieuwegein | |
| Netherlands | GSK Investigational Site | Rotterdam | |
| Netherlands | GSK Investigational Site | Sneek | |
| Netherlands | GSK Investigational Site | Spijkenisse | |
| Netherlands | GSK Investigational Site | Veldhoven | |
| Netherlands | GSK Investigational Site | Zutphen | |
| Netherlands | GSK Investigational Site | Zwolle | |
| New Zealand | GSK Investigational Site | Auckland | |
| New Zealand | GSK Investigational Site | Dunedin | |
| New Zealand | GSK Investigational Site | Newtown, Wellington | |
| New Zealand | GSK Investigational Site | Tauranga | |
| New Zealand | GSK Investigational Site | Tauranga | |
| New Zealand | GSK Investigational Site | Wellington | |
| Norway | GSK Investigational Site | Bodø | |
| Norway | GSK Investigational Site | Fredrikstad | |
| Norway | GSK Investigational Site | Hakadal | |
| Norway | GSK Investigational Site | Kløfta | |
| Norway | GSK Investigational Site | Levanger | |
| Norway | GSK Investigational Site | Oslo | |
| Norway | GSK Investigational Site | Stavanger | |
| Norway | GSK Investigational Site | Stavanger | |
| Norway | GSK Investigational Site | Trondheim | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Lima | |
| Peru | GSK Investigational Site | Pueblo Libre | Lima |
| Peru | GSK Investigational Site | San Martin de Porres | Lima |
| Peru | GSK Investigational Site | San Miguel | Lima |
| Philippines | GSK Investigational Site | Caloocan City | |
| Philippines | GSK Investigational Site | Iloilo | |
| Philippines | GSK Investigational Site | Jaro, Iloilo City | |
| Philippines | GSK Investigational Site | Pasig | |
| Philippines | GSK Investigational Site | Quezon City | |
| Poland | GSK Investigational Site | Bialystok | |
| Poland | GSK Investigational Site | Ostrowiec Swietokrzyski | |
| Poland | GSK Investigational Site | Sopot | |
| Poland | GSK Investigational Site | Szczecin | |
| Poland | GSK Investigational Site | Tarnów | |
| Poland | GSK Investigational Site | Zgierz | |
| Puerto Rico | GSK Investigational Site | Guaynabo | |
| Puerto Rico | GSK Investigational Site | Mayaguez | |
| Puerto Rico | GSK Investigational Site | Ponce | |
| Puerto Rico | GSK Investigational Site | San Juan | |
| Puerto Rico | GSK Investigational Site | San Juan | |
| Romania | GSK Investigational Site | Braila | |
| Romania | GSK Investigational Site | Brasov | |
| Romania | GSK Investigational Site | Bucharest | |
| Romania | GSK Investigational Site | Comuna Alexandru Cel Bun | |
| Romania | GSK Investigational Site | Constanta | |
| Romania | GSK Investigational Site | Ploiesti | |
| Romania | GSK Investigational Site | Ploiesti | |
| Romania | GSK Investigational Site | Ramnicu Valcea | |
| Russian Federation | GSK Investigational Site | Barnaul | |
| Russian Federation | GSK Investigational Site | Belgorod | |
| Russian Federation | GSK Investigational Site | Blagoveshchensk | |
| Russian Federation | GSK Investigational Site | Chita | |
| Russian Federation | GSK Investigational Site | Chita | |
| Russian Federation | GSK Investigational Site | Ekaterinburg | |
| Russian Federation | GSK Investigational Site | Ivanovo | |
| Russian Federation | GSK Investigational Site | Kazan | |
| Russian Federation | GSK Investigational Site | Kazan | |
| Russian Federation | GSK Investigational Site | Krasnodar | |
| Russian Federation | GSK Investigational Site | Krasnoyarsk | |
| Russian Federation | GSK Investigational Site | Moscow | |
| Russian Federation | GSK Investigational Site | Moscow | |
| Russian Federation | GSK Investigational Site | Novgorod | |
| Russian Federation | GSK Investigational Site | Novosibirsk | |
| Russian Federation | GSK Investigational Site | Petrozavodsk | |
| Russian Federation | GSK Investigational Site | Pyatigorsk | |
| Russian Federation | GSK Investigational Site | Ryazan | |
| Russian Federation | GSK Investigational Site | Ryazan | |
| Russian Federation | GSK Investigational Site | Saint-Petersburg | |
| Russian Federation | GSK Investigational Site | Saratov | |
| Russian Federation | GSK Investigational Site | St. Petersburg | |
| Russian Federation | GSK Investigational Site | St. Petersburg | |
| Russian Federation | GSK Investigational Site | Stavropol | |
| Russian Federation | GSK Investigational Site | Tomsk | |
| Russian Federation | GSK Investigational Site | Tomsk | |
| Russian Federation | GSK Investigational Site | Ulan-Ude | |
| Russian Federation | GSK Investigational Site | Ulyanovsk | |
| Russian Federation | GSK Investigational Site | Vladimir | |
| Russian Federation | GSK Investigational Site | Vladivostok | |
| Russian Federation | GSK Investigational Site | Vladivostok | |
| Russian Federation | GSK Investigational Site | Volgodonsk | |
| Russian Federation | GSK Investigational Site | Voronezh | |
| Russian Federation | GSK Investigational Site | Vsevolozhsk, Leningrad Region | |
| Russian Federation | GSK Investigational Site | Yaroslavl | |
| Russian Federation | GSK Investigational Site | Yaroslavl | |
| Singapore | GSK Investigational Site | Singapore | |
| Singapore | GSK Investigational Site | Singapore | |
| Singapore | GSK Investigational Site | Singapore | |
| Singapore | GSK Investigational Site | Singapore | |
| South Africa | GSK Investigational Site | Amanzimtoti | |
| South Africa | GSK Investigational Site | Bellville | |
| South Africa | GSK Investigational Site | Benoni | Gauteng |
| South Africa | GSK Investigational Site | Bloemfontein | |
| South Africa | GSK Investigational Site | Boksburg | Gauteng |
| South Africa | GSK Investigational Site | Boksburg North | |
| South Africa | GSK Investigational Site | Cape Town | |
| South Africa | GSK Investigational Site | Cape Town | |
| South Africa | GSK Investigational Site | CapeTown | |
| South Africa | GSK Investigational Site | Durban | |
| South Africa | GSK Investigational Site | Durban | |
| South Africa | GSK Investigational Site | Gatesville | |
| South Africa | GSK Investigational Site | Johannesburg | |
| South Africa | GSK Investigational Site | Korsten | |
| South Africa | GSK Investigational Site | Middelburg | Mpumalanga |
| South Africa | GSK Investigational Site | Mowbray | |
| South Africa | GSK Investigational Site | Paarl | |
| South Africa | GSK Investigational Site | Panorama | |
| South Africa | GSK Investigational Site | Pretoria | Gauteng |
| South Africa | GSK Investigational Site | Tygerberg | |
| South Africa | GSK Investigational Site | Val De Grace, Pretoria | Gauteng |
| Spain | GSK Investigational Site | (Badalona) Barcelona | |
| Spain | GSK Investigational Site | (Barakaldo) Vizcaya | |
| Spain | GSK Investigational Site | Alicante | |
| Spain | GSK Investigational Site | Alzira/Valencia | |
| Spain | GSK Investigational Site | Badalona | Catalonia |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Barcelona | |
| Spain | GSK Investigational Site | Basurto/Bilbao | |
| Spain | GSK Investigational Site | Burgos | |
| Spain | GSK Investigational Site | Cáceres | |
| Spain | GSK Investigational Site | Centelles (Barcelona) | |
| Spain | GSK Investigational Site | Coslada | |
| Spain | GSK Investigational Site | Gerona | |
| Spain | GSK Investigational Site | Girona | |
| Spain | GSK Investigational Site | L'Hospitalet de Llobregat | |
| Spain | GSK Investigational Site | La Coruña | |
| Spain | GSK Investigational Site | La Coruña | |
| Spain | GSK Investigational Site | La Roca Del Valles (Barcelona) | |
| Spain | GSK Investigational Site | Laredo | Cantabria |
| Spain | GSK Investigational Site | Lleida | |
| Spain | GSK Investigational Site | Madrid | |
| Spain | GSK Investigational Site | Madrid | |
| Spain | GSK Investigational Site | Málaga | |
| Spain | GSK Investigational Site | Marbella - Málaga | Andalucia |
| Spain | GSK Investigational Site | Mataró | |
| Spain | GSK Investigational Site | Mérida (Badajoz) | |
| Spain | GSK Investigational Site | Oviedo | |
| Spain | GSK Investigational Site | Palma de Mallorca | |
| Spain | GSK Investigational Site | Pamplona | |
| Spain | GSK Investigational Site | Peralada( Girona) | |
| Spain | GSK Investigational Site | Petrer/Alicante | |
| Spain | GSK Investigational Site | Ponferrada (León) | |
| Spain | GSK Investigational Site | Pozuelo De Alarcón/Madrid | |
| Spain | GSK Investigational Site | Sabadell (Barcelona) | |
| Spain | GSK Investigational Site | Sagunto/Valencia | |
| Spain | GSK Investigational Site | Salamanca | |
| Spain | GSK Investigational Site | San Juan De Alicante | |
| Spain | GSK Investigational Site | San Sebastian de los Reyes | |
| Spain | GSK Investigational Site | Santander | |
| Spain | GSK Investigational Site | Santiago de Compostela | |
| Spain | GSK Investigational Site | Sevilla | |
| Spain | GSK Investigational Site | Tarragona | |
| Spain | GSK Investigational Site | Torrelavega | Cantabria |
| Spain | GSK Investigational Site | Valencia | |
| Spain | GSK Investigational Site | Valencia | |
| Spain | GSK Investigational Site | Valladolid | |
| Spain | GSK Investigational Site | Vizcaya | |
| Spain | GSK Investigational Site | Zaragoza | |
| Sweden | GSK Investigational Site | Borås | |
| Sweden | GSK Investigational Site | Göteborg | |
| Sweden | GSK Investigational Site | Göteborg | |
| Sweden | GSK Investigational Site | Höllviken | |
| Sweden | GSK Investigational Site | Linköping | |
| Sweden | GSK Investigational Site | Luleå | |
| Sweden | GSK Investigational Site | Örebro | |
| Sweden | GSK Investigational Site | Östersund | |
| Sweden | GSK Investigational Site | Stockholm | |
| Sweden | GSK Investigational Site | Uppsala | |
| Thailand | GSK Investigational Site | Bangkok | |
| Thailand | GSK Investigational Site | Bangkok | |
| Thailand | GSK Investigational Site | Chiangmai | |
| Thailand | GSK Investigational Site | Khon Kaen | |
| Thailand | GSK Investigational Site | Muang | |
| Thailand | GSK Investigational Site | Nakhon Ratchasima | |
| Thailand | GSK Investigational Site | Nan | |
| Thailand | GSK Investigational Site | Songkla | |
| Turkey | GSK Investigational Site | Ankara | |
| Turkey | GSK Investigational Site | Istanbul | |
| Turkey | GSK Investigational Site | Istanbul | |
| Turkey | GSK Investigational Site | Izmir | |
| Turkey | GSK Investigational Site | Mersin | |
| Ukraine | GSK Investigational Site | Kharkiv | |
| Ukraine | GSK Investigational Site | Kharkiv | |
| Ukraine | GSK Investigational Site | Kiev | |
| Ukraine | GSK Investigational Site | Kyiv | |
| Ukraine | GSK Investigational Site | Kyiv | |
| Ukraine | GSK Investigational Site | Kyiv | |
| Ukraine | GSK Investigational Site | Mykolayiv | |
| Ukraine | GSK Investigational Site | Odesa | |
| Ukraine | GSK Investigational Site | Sumy | |
| Ukraine | GSK Investigational Site | Vinnytsia | |
| United Kingdom | GSK Investigational Site | Baillieston, Glasgow | |
| United Kingdom | GSK Investigational Site | Blackpool | Lancashire |
| United Kingdom | GSK Investigational Site | Bradford | |
| United Kingdom | GSK Investigational Site | Bradford on Avon | Wiltshire |
| United Kingdom | GSK Investigational Site | Cambridge | |
| United Kingdom | GSK Investigational Site | Chester | |
| United Kingdom | GSK Investigational Site | Crawley | |
| United Kingdom | GSK Investigational Site | Crownhill, Plymouth | |
| United Kingdom | GSK Investigational Site | Dundee, Scotland | |
| United Kingdom | GSK Investigational Site | Exeter | Devon |
| United Kingdom | GSK Investigational Site | High Heaton, Newcastle Upon Tyne | Tyne & Wear |
| United Kingdom | GSK Investigational Site | Northwood | Middlesex |
| United Kingdom | GSK Investigational Site | Sidcup, Kent | |
| United Kingdom | GSK Investigational Site | Stockton-on-Tees | |
| United Kingdom | GSK Investigational Site | Trowbridge | |
| United Kingdom | GSK Investigational Site | Wishaw | Lanarkshire |
| United States | GSK Investigational Site | Abingdon | Virginia |
| United States | GSK Investigational Site | Adairsville | Georgia |
| United States | GSK Investigational Site | Albany | New York |
| United States | GSK Investigational Site | Albuquerque | New Mexico |
| United States | GSK Investigational Site | Anderson | South Carolina |
| United States | GSK Investigational Site | Ann Arbor | Michigan |
| United States | GSK Investigational Site | Arcadia | California |
| United States | GSK Investigational Site | Asheville | North Carolina |
| United States | GSK Investigational Site | Athens | Alabama |
| United States | GSK Investigational Site | Athens | Georgia |
| United States | GSK Investigational Site | Austell | Georgia |
| United States | GSK Investigational Site | Bakersfield | California |
| United States | GSK Investigational Site | Bangor | Maine |
| United States | GSK Investigational Site | Bay Pines | Florida |
| United States | GSK Investigational Site | Bellingham | Washington |
| United States | GSK Investigational Site | Birmingham | Alabama |
| United States | GSK Investigational Site | Birmingham | Alabama |
| United States | GSK Investigational Site | Birmingham | Alabama |
| United States | GSK Investigational Site | Boulder | Colorado |
| United States | GSK Investigational Site | Boynton Beach | Florida |
| United States | GSK Investigational Site | Brandon | Florida |
| United States | GSK Investigational Site | Bronx | New York |
| United States | GSK Investigational Site | Bronx | New York |
| United States | GSK Investigational Site | Bronxville | New York |
| United States | GSK Investigational Site | Butte | Montana |
| United States | GSK Investigational Site | Calabash | North Carolina |
| United States | GSK Investigational Site | Canton | Ohio |
| United States | GSK Investigational Site | Celebration | Florida |
| United States | GSK Investigational Site | Chandler | Arizona |
| United States | GSK Investigational Site | Charleston | South Carolina |
| United States | GSK Investigational Site | Charlotte | North Carolina |
| United States | GSK Investigational Site | Charlotte | North Carolina |
| United States | GSK Investigational Site | Charlotte | North Carolina |
| United States | GSK Investigational Site | Chattanooga | Tennessee |
| United States | GSK Investigational Site | Chesterfield | Missouri |
| United States | GSK Investigational Site | Chicago | Illinois |
| United States | GSK Investigational Site | Chula Vista | California |
| United States | GSK Investigational Site | Cincinnati | Ohio |
| United States | GSK Investigational Site | Cincinnati | Ohio |
| United States | GSK Investigational Site | Cincinnati | Ohio |
| United States | GSK Investigational Site | Clearwater | Florida |
| United States | GSK Investigational Site | Clearwater | Florida |
| United States | GSK Investigational Site | Coeur d'Alene | Idaho |
| United States | GSK Investigational Site | Colorado Springs | Colorado |
| United States | GSK Investigational Site | Columbia | Maryland |
| United States | GSK Investigational Site | Columbia | South Carolina |
| United States | GSK Investigational Site | Columbia | South Carolina |
| United States | GSK Investigational Site | Columbus | Ohio |
| United States | GSK Investigational Site | Columbus | Georgia |
| United States | GSK Investigational Site | Conyers | Georgia |
| United States | GSK Investigational Site | Corsicana | Texas |
| United States | GSK Investigational Site | Corvallis | Oregon |
| United States | GSK Investigational Site | Council Bluffs | Iowa |
| United States | GSK Investigational Site | Crowley | Louisiana |
| United States | GSK Investigational Site | Danbury | Connecticut |
| United States | GSK Investigational Site | Dayton | Ohio |
| United States | GSK Investigational Site | Daytona Beach | Florida |
| United States | GSK Investigational Site | Decatur | Georgia |
| United States | GSK Investigational Site | DeLand | Florida |
| United States | GSK Investigational Site | Downingtown | Pennsylvania |
| United States | GSK Investigational Site | Doylestown | Pennsylvania |
| United States | GSK Investigational Site | Duluth | Georgia |
| United States | GSK Investigational Site | Duluth | Minnesota |
| United States | GSK Investigational Site | Durham | North Carolina |
| United States | GSK Investigational Site | Easley | South Carolina |
| United States | GSK Investigational Site | East Providence | Rhode Island |
| United States | GSK Investigational Site | Edgewater | Florida |
| United States | GSK Investigational Site | Edina | Minnesota |
| United States | GSK Investigational Site | Edinburg | Texas |
| United States | GSK Investigational Site | Elizabeth City | North Carolina |
| United States | GSK Investigational Site | Elk Grove Village | Illinois |
| United States | GSK Investigational Site | Encinitas | California |
| United States | GSK Investigational Site | Erie | Pennsylvania |
| United States | GSK Investigational Site | Escondido | California |
| United States | GSK Investigational Site | Evansville | Indiana |
| United States | GSK Investigational Site | Everett | Washington |
| United States | GSK Investigational Site | Fall River | Massachusetts |
| United States | GSK Investigational Site | Flagstaff | Arizona |
| United States | GSK Investigational Site | Florence | Alabama |
| United States | GSK Investigational Site | Fort Collins | Colorado |
| United States | GSK Investigational Site | Fort Lauderdale | Florida |
| United States | GSK Investigational Site | Fort Mill | South Carolina |
| United States | GSK Investigational Site | Fort Mitchell | Kentucky |
| United States | GSK Investigational Site | Fort Myers | Florida |
| United States | GSK Investigational Site | Fort Worth | Texas |
| United States | GSK Investigational Site | Franklin | Indiana |
| United States | GSK Investigational Site | Fremont | Nebraska |
| United States | GSK Investigational Site | Fridley | Minnesota |
| United States | GSK Investigational Site | Gaffney | South Carolina |
| United States | GSK Investigational Site | Gaffney | South Carolina |
| United States | GSK Investigational Site | Gainesville | Georgia |
| United States | GSK Investigational Site | Gainesville | Florida |
| United States | GSK Investigational Site | Gastonia | North Carolina |
| United States | GSK Investigational Site | Gillespie | Illinois |
| United States | GSK Investigational Site | Glendale | Arizona |
| United States | GSK Investigational Site | Golden | Colorado |
| United States | GSK Investigational Site | Gonzales | Texas |
| United States | GSK Investigational Site | Grand Island | Nebraska |
| United States | GSK Investigational Site | Greenfield | Indiana |
| United States | GSK Investigational Site | Greensboro | North Carolina |
| United States | GSK Investigational Site | Greenville | South Carolina |
| United States | GSK Investigational Site | Hampton | Virginia |
| United States | GSK Investigational Site | Hartford | Connecticut |
| United States | GSK Investigational Site | Hendersonville | Tennessee |
| United States | GSK Investigational Site | Hendersonville | North Carolina |
| United States | GSK Investigational Site | Hines | Illinois |
| United States | GSK Investigational Site | Hollywood | Maryland |
| United States | GSK Investigational Site | Hollywood | Florida |
| United States | GSK Investigational Site | Houston | Texas |
| United States | GSK Investigational Site | Houston | Texas |
| United States | GSK Investigational Site | Houston | Texas |
| United States | GSK Investigational Site | Huntersville | North Carolina |
| United States | GSK Investigational Site | Huntington Beach | California |
| United States | GSK Investigational Site | Iowa City | Iowa |
| United States | GSK Investigational Site | Jackson | Mississippi |
| United States | GSK Investigational Site | Jacksonville | Florida |
| United States | GSK Investigational Site | Jacksonville | Florida |
| United States | GSK Investigational Site | Jacksonville | Florida |
| United States | GSK Investigational Site | Jacksonville | Florida |
| United States | GSK Investigational Site | Jacksonville | Florida |
| United States | GSK Investigational Site | Jasper | Alabama |
| United States | GSK Investigational Site | Johnson City | Tennessee |
| United States | GSK Investigational Site | Johnstown | Pennsylvania |
| United States | GSK Investigational Site | Kansas City | Missouri |
| United States | GSK Investigational Site | Katy | Texas |
| United States | GSK Investigational Site | Kerrville | Texas |
| United States | GSK Investigational Site | Kingwood | Texas |
| United States | GSK Investigational Site | Lafayette | Louisiana |
| United States | GSK Investigational Site | Las Vegas | Nevada |
| United States | GSK Investigational Site | Leesburg | Florida |
| United States | GSK Investigational Site | Lewisville | Texas |
| United States | GSK Investigational Site | Lexington | North Carolina |
| United States | GSK Investigational Site | Lincoln | Nebraska |
| United States | GSK Investigational Site | Long Beach | California |
| United States | GSK Investigational Site | Long Beach | California |
| United States | GSK Investigational Site | Longview | Texas |
| United States | GSK Investigational Site | Louisville | Kentucky |
| United States | GSK Investigational Site | Loxahatchee Groves | Florida |
| United States | GSK Investigational Site | Lynchburg | Virginia |
| United States | GSK Investigational Site | Maitland | Florida |
| United States | GSK Investigational Site | Marietta | Georgia |
| United States | GSK Investigational Site | Marion | Ohio |
| United States | GSK Investigational Site | Marlton | New Jersey |
| United States | GSK Investigational Site | Medford | Oregon |
| United States | GSK Investigational Site | Miami | Florida |
| United States | GSK Investigational Site | Miami | Florida |
| United States | GSK Investigational Site | Middleburg Heights | Ohio |
| United States | GSK Investigational Site | Minneapolis | Minnesota |
| United States | GSK Investigational Site | Minneapolis | Minnesota |
| United States | GSK Investigational Site | Mission Hills | California |
| United States | GSK Investigational Site | Missoula | Montana |
| United States | GSK Investigational Site | Mobile | Alabama |
| United States | GSK Investigational Site | Modesto | California |
| United States | GSK Investigational Site | Moorestown | New Jersey |
| United States | GSK Investigational Site | Mooresville | North Carolina |
| United States | GSK Investigational Site | Mount Pleasant | South Carolina |
| United States | GSK Investigational Site | Muncie | Indiana |
| United States | GSK Investigational Site | Muscle Shoals | Alabama |
| United States | GSK Investigational Site | Neptune | New Jersey |
| United States | GSK Investigational Site | New Haven | Connecticut |
| United States | GSK Investigational Site | New Orleans | Louisiana |
| United States | GSK Investigational Site | New Orleans | Louisiana |
| United States | GSK Investigational Site | New Orleans | Louisiana |
| United States | GSK Investigational Site | New Port Richey | Florida |
| United States | GSK Investigational Site | New York | New York |
| United States | GSK Investigational Site | New York | New York |
| United States | GSK Investigational Site | New York | New York |
| United States | GSK Investigational Site | Newport Beach | California |
| United States | GSK Investigational Site | North Dartmouth | Massachusetts |
| United States | GSK Investigational Site | O'Fallon | Illinois |
| United States | GSK Investigational Site | Oak Park | Illinois |
| United States | GSK Investigational Site | Olathe | Kansas |
| United States | GSK Investigational Site | Omaha | Nebraska |
| United States | GSK Investigational Site | Omaha | Nebraska |
| United States | GSK Investigational Site | Orlando | Florida |
| United States | GSK Investigational Site | Oviedo | Florida |
| United States | GSK Investigational Site | Paducah | Kentucky |
| United States | GSK Investigational Site | Palo Alto | California |
| United States | GSK Investigational Site | Pembroke Pines | Florida |
| United States | GSK Investigational Site | Pensacola | Florida |
| United States | GSK Investigational Site | Peoria | Arizona |
| United States | GSK Investigational Site | Philadelphia | Pennsylvania |
| United States | GSK Investigational Site | Philadelphia | Pennsylvania |
| United States | GSK Investigational Site | Philadelphia | Pennsylvania |
| United States | GSK Investigational Site | Phoenix | Arizona |
| United States | GSK Investigational Site | Phoenix | Arizona |
| United States | GSK Investigational Site | Phoenixville | Pennsylvania |
| United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
| United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
| United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
| United States | GSK Investigational Site | Pittsfield | Massachusetts |
| United States | GSK Investigational Site | Plano | Texas |
| United States | GSK Investigational Site | Ponte Vedra Beach | Florida |
| United States | GSK Investigational Site | Port Charlotte | Florida |
| United States | GSK Investigational Site | Port Charlotte | Florida |
| United States | GSK Investigational Site | Port Orange | Florida |
| United States | GSK Investigational Site | Portland | Oregon |
| United States | GSK Investigational Site | Portland | Oregon |
| United States | GSK Investigational Site | Portland | Oregon |
| United States | GSK Investigational Site | Quincy | Illinois |
| United States | GSK Investigational Site | Rapid City | South Dakota |
| United States | GSK Investigational Site | Reno | Nevada |
| United States | GSK Investigational Site | Renton | Washington |
| United States | GSK Investigational Site | Renton | Washington |
| United States | GSK Investigational Site | Reseda | California |
| United States | GSK Investigational Site | Richmond | Virginia |
| United States | GSK Investigational Site | Richmond | Virginia |
| United States | GSK Investigational Site | Richmond | Virginia |
| United States | GSK Investigational Site | Rincon | Georgia |
| United States | GSK Investigational Site | Riverside | California |
| United States | GSK Investigational Site | Rochester | Minnesota |
| United States | GSK Investigational Site | Rock Hill | South Carolina |
| United States | GSK Investigational Site | Rolling Hills Estates | California |
| United States | GSK Investigational Site | Sacramento | California |
| United States | GSK Investigational Site | Saint Charles | Missouri |
| United States | GSK Investigational Site | Saint Louis | Missouri |
| United States | GSK Investigational Site | Saint Paul | Minnesota |
| United States | GSK Investigational Site | Saint Petersburg | Florida |
| United States | GSK Investigational Site | San Antonio | Texas |
| United States | GSK Investigational Site | San Antonio | Texas |
| United States | GSK Investigational Site | San Diego | California |
| United States | GSK Investigational Site | Santa Ana | California |
| United States | GSK Investigational Site | Santa Monica | California |
| United States | GSK Investigational Site | Sarasota | Florida |
| United States | GSK Investigational Site | Sealy | Texas |
| United States | GSK Investigational Site | Seattle | Washington |
| United States | GSK Investigational Site | Seneca | South Carolina |
| United States | GSK Investigational Site | Sheffield | Alabama |
| United States | GSK Investigational Site | Shelby | North Carolina |
| United States | GSK Investigational Site | Shelby | North Carolina |
| United States | GSK Investigational Site | Shreveport | Louisiana |
| United States | GSK Investigational Site | Sioux Falls | South Dakota |
| United States | GSK Investigational Site | Southfield | Michigan |
| United States | GSK Investigational Site | Spartanburg | South Carolina |
| United States | GSK Investigational Site | Spokane Valley | Washington |
| United States | GSK Investigational Site | Stamford | Connecticut |
| United States | GSK Investigational Site | Sugar Land | Texas |
| United States | GSK Investigational Site | Sunset | Louisiana |
| United States | GSK Investigational Site | Syracuse | New York |
| United States | GSK Investigational Site | Tabor City | North Carolina |
| United States | GSK Investigational Site | Tacoma | Washington |
| United States | GSK Investigational Site | Tampa | Florida |
| United States | GSK Investigational Site | Tipton | Pennsylvania |
| United States | GSK Investigational Site | Toledo | Ohio |
| United States | GSK Investigational Site | Toledo | Ohio |
| United States | GSK Investigational Site | Tomball | Texas |
| United States | GSK Investigational Site | Topeka | Kansas |
| United States | GSK Investigational Site | Torrance | California |
| United States | GSK Investigational Site | Troy | Michigan |
| United States | GSK Investigational Site | Tucson | Arizona |
| United States | GSK Investigational Site | Tucson | Arizona |
| United States | GSK Investigational Site | Tucson | Arizona |
| United States | GSK Investigational Site | Tustin | California |
| United States | GSK Investigational Site | Union | South Carolina |
| United States | GSK Investigational Site | Upland | California |
| United States | GSK Investigational Site | Virginia Beach | Virginia |
| United States | GSK Investigational Site | Vista | California |
| United States | GSK Investigational Site | Waterbury | Connecticut |
| United States | GSK Investigational Site | West Haven | Connecticut |
| United States | GSK Investigational Site | Whiteville | North Carolina |
| United States | GSK Investigational Site | Wichita | Kansas |
| United States | GSK Investigational Site | Wilmington | North Carolina |
| United States | GSK Investigational Site | Winfield | Illinois |
| United States | GSK Investigational Site | Winston-Salem | North Carolina |
| United States | GSK Investigational Site | Woodbury | Minnesota |
| United States | GSK Investigational Site | Woodstock | Georgia |
| United States | GSK Investigational Site | Wooster | Ohio |
| United States | GSK Investigational Site | Worcester | Massachusetts |
| United States | GSK Investigational Site | Wyomissing | Pennsylvania |
| Vietnam | GSK Investigational Site | Ha Noi | |
| Vietnam | GSK Investigational Site | Ho Chi Minh |
| Lead Sponsor | Collaborator |
|---|---|
| GlaxoSmithKline |
United States, Vietnam, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Israel, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Peru, Philippines, Poland, Puerto Rico, Romania, Russian Federation, Singapore, South Africa, Spain, Sweden, Thailand, Turkey, Ukraine, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI | The annual rate of moderate or severe COPD exacerbations which occurred during treatment was assessed. Moderate exacerbations were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Analysis performed using a generalized linear model assuming a negative binomial distribution. ITT population was used which comprised of all randomized participants, excluding those who were randomized in error. Only those participants with non-missing co-variates were included in the analysis. | Up to Week 52 | |
| Secondary | Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1), at Week 52 Comparing FF/UMEC/VI With FF/VI | FEV1 was defined as the amount of air a person exhales in one second. Change from Baseline was calculated as the value of FEV1 at Week 52 minus the value at Baseline. Baseline for trough FEV1 was defined as Day 1 (Pre-dose). Only those participants with non-missing co-variates were included in the analysis. The analysis was performed using a Repeated measures model with covariates of treatment group, smoking status (Screening), geographical region, visit, Baseline, Baseline by visit and treatment group by visit interactions. | Baseline and Week 52 | |
| Secondary | Change From Baseline in St. George's Respiratory Questionnaire for (SGRQ) Total Score at Week 52 Comparing FF/UMEC/VI With FF/VI | SGRQ is a disease specific-questionnaire, designed to measure impact of respiratory disease and its treatment on a COPD participant's Health Related Quality of Life (HRQoL). SGRQ contains 14 questions with total of 40 items grouped into three domains (Symptoms, Activity, and Impacts). The overall summary score along with scores for the individual domains of symptoms, activity and impacts were assessed. Score was calculated by summing the pre-assigned weights of answers, dividing by sum of maximum weights for items in SGRQ. Total scores ranged from 0 to 100. A decrease in score indicates improvement in HRQoL and higher score implies worse quality of life. Change from Baseline was calculated as total score at Week 52 minus value at Baseline. Baseline was defined as Day 1. Minimum clinically important difference (MCID) for this instrument is a 4-point improvement (decrease from Baseline). Only those participants with non-missing co-variates were included in the analysis. | Baseline and Week 52 | |
| Secondary | Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With FF/VI and With UMEC/VI | This measures the number of days, to the first onset of moderate or severe exacerbations. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. The Hazard ratio from Cox proportional hazards model with covariates of treatment group, sex, exacerbation history (<=1, >=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening), have been reported. Only those participants with non-missing co-variates were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If <25% (and <50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment. | Up to Week 52 | |
| Secondary | Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI in the Subset of Participants With a Blood Eosinophil Count >=150 Cells Per Microliter | The annual rate of moderate or severe COPD exacerbations during the treatment, for participants with blood eosinophil count >=150 cells per microliter , has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non-missing eosinophil, at Baseline were included in the analysis. | Up to Week 52 | |
| Secondary | Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With UMEC/VI in the Subset of Particpants With a Blood Eosinophil Count >=150 Cells Per Microliter at Baseline | This measures the number of days, to the first onset of moderate or severe exacerbations for participants with blood eosinophil count >=150 cells per microliter, at Baseline has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non missing eosinophils at Baseline were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If <25% (and <50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment. | Up to Week 52 | |
| Secondary | Annual Rate of On-treatment Severe Exacerbations Comparing FF/UMEC/VI With FF/VI and With UMEC/VI | The annual rate of severe COPD exacerbations during the treatment, has been reported. Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. The covariates of treatment group, sex, exacerbation history (<=1, >=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening) were used. Only those participants with non-missing co-variates were included in the analysis | Up to Week 52 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
| Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
| Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
| Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
| Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
| Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
| Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
| Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
| Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
| Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
| Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
| Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
| Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
| Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
| Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
| Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|